Cytek Biosciences Inc. (CTKB)

NASDAQ: CTKB · Real-Time Price · USD

3.73

0.02 (0.54%)

At close: May 01, 2025, 3:33 PM

0.54% (1D)

Bid	3.72
Market Cap	476.58M
Revenue (ttm)	176.63M
Net Income (ttm)	-6.02M
EPS (ttm)	-0.05
PE Ratio (ttm)	-74.7
Forward PE	74.2
Analyst	Buy

Ask	3.74
Volume	274,619
Avg. Volume (20D)	831,942
Open	3.74
Previous Close	3.71
Day's Range	3.62 - 3.75
52-Week Range	3.27 - 7.63
Beta	1.41

About CTKB

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system, which leverages full sp...

[Read more]

Industry Medical - Devices

Sector Healthcare

IPO Date Jul 23, 2021

Employees 648

Stock Exchange NASDAQ

Ticker Symbol CTKB

Website https://cytekbio.com

Full Company Profile

Analyst Forecast

According to 2 analyst ratings, the average rating for CTKB stock is "Buy." The 12-month stock price forecast is $7, which is an increase of 87.42% from the latest price.

Stock Forecasts

Next Earnings Release

Cytek Biosciences Inc. is scheduled to release its earnings on May 8, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

-6.65%

Cytek Biosciences shares are trading lower after t... Unlock content with Pro Subscription

5 months ago

+36.03%

Cytek Biosciences shares are trading higher after the company reported better-than-expected Q3 financial results.

News

2 days ago · seekingalpha.com

Why Cytek Biosciences Should Beat Q1 Earnings Expectations

There are still growth drivers that may positively play out in future quarters, so I'm still optimistic on Cytek Biosciences. Cytek's FY2024 adjusted EBITDA surged 77% YoY, indicating robust profitabi...

2 months ago · seekingalpha.com

Cytek Biosciences, Inc. (CTKB) Q4 2024 Earnings Conference Call Transcript

Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Paul Goodson - IR Wenbin Jiang - CEO William McCombe - CFO Conference Call Par...

2 months ago · zacks.com

Cytek Biosciences, Inc. (CTKB) Tops Q4 Earnings Estimates

Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.07 per share a year ago.